XML 20 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8
SHAREHOLDERS' EQUITY (Details) (USD $)
 0 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 7 Months Ended 1 Months Ended 6 Months Ended 6 Months Ended 6 Months Ended 12 Months Ended
Jan. 22, 2013
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
As Reported
Jun. 30, 2012
As Reported
Jun. 30, 2013
As Reported
Jun. 30, 2012
As Reported
Jun. 30, 2013
Restatement adjustment
Jun. 30, 2012
Restatement adjustment
Jun. 30, 2013
Restatement adjustment
Jun. 30, 2012
Restatement adjustment
Mar. 31, 2013
Rights offering
item
Mar. 31, 2013
RCF
Short term financing
Dec. 31, 2012
RCF
Short term financing
Aug. 13, 2013
RCF
Short term financing
Mar. 31, 2013
RCF
Rights offering
Short term financing
Jun. 30, 2013
Common Stock
Dec. 31, 2012
Common Stock
As Reported
Jun. 30, 2013
Paid-In Capital
Dec. 31, 2012
Paid-In Capital
As Reported
Jun. 30, 2013
Accumulated Deficit
Dec. 31, 2012
Accumulated Deficit
As Reported
Dec. 31, 2012
Accumulated Deficit
Restatement adjustment
Jun. 30, 2013
Treasury Stock
Dec. 31, 2012
Treasury Stock
Dec. 31, 2012
Treasury Stock
As Reported
SHAREHOLDERS' EQUITY                                                        
Reverse stock split ratio 0.1                                                      
Common stock outstanding before reverse stock split (in shares) 161,100,000                                                      
Common stock, shares outstanding 16,100,000 19,820,258   19,820,258                             19,820,258 16,150,163                
Changes in shareholders equity                                                        
Balance at the beginning of the period (in shares)       16,150,163                             16,150,163 16,150,163                
Balance at the beginning of the period       $ 36,169,042                             $ 16,154 $ 16,154 $ 207,338,549 $ 207,338,549 $ (171,176,243) $ (162,201,908)   $ (9,418) $ (9,418) $ (9,418)
Prior period adjustment                                                 (8,974,335)      
Net loss, as restated   (4,196,700) (5,234,065) (8,670,147) (9,443,730) (3,846,586) (3,660,679) (7,997,178) (7,267,149) (350,114) (1,573,386) (672,969) (2,176,581)                   (8,670,147)          
Stock compensation expense                                         183,316              
Common stock issued - payment of loan principal and interest (in shares)                                 31,343   1,992,127                  
Common stock issued - payment of loan principal and interest                                     1,992   5,093,841              
Common stock issued - shareholder rights offering (in shares)                                     1,547,843                  
Common stock issued - shareholder rights offering                                     1,548   3,597,884              
Common stock issued for services (in shares)                                     83,200                  
Common stock issued for services       291,500                             83   291,417              
Restricted stock issuance (in shares)                                     246,925                  
Restricted stock issuance       47 341                           47   (47)              
Balance at the end of the period (in shares) 16,100,000 19,820,258   19,820,258                             19,820,258 16,150,163                
Balance at the end of the period   36,668,976   36,668,976   46,316,280   46,316,280   (9,647,304)   (9,647,304)             19,824 16,154 216,504,960 207,338,549 (179,846,390) (162,201,908)   (9,418) (9,418) (9,418)
Short term financing repaid                                   5,000,000                    
Number of shares of common stock issued upon conversion                                   1,960,000                    
Interest accrued on the loan                             79,167 16,667                        
Number of subscription rights issued for each share of common stock owned or subject to a warrant                           1                            
Number of non-transferrable subscription rights received (in shares)                           0.3119                            
Exercise price (in dollars per share)                           $ 2.55                            
Net proceeds from sale of shares of common stock in cash                           $ 3,600,000